Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium
暂无分享,去创建一个
S. Cross | M. Beckmann | P. Fasching | A. Olshan | N. Camp | D. Noh | C. Vachon | Jingmei Li | K. Czene | P. Hall | F. Couch | A. Schneeweiss | H. Brenner | J. Chang-Claude | S. Chanock | M. García-Closas | D. Hunter | A. Wolk | H. Becher | G. Giles | J. Hopper | C. Haiman | T. Dörk | M. Southey | A. Cox | D. Easton | P. Kraft | R. Tamimi | G. Rennert | Chen-Yang Shen | D. Lambrechts | L. Le Marchand | D. Stram | V. Kristensen | X. Shu | W. Zheng | A. Ziogas | H. Anton-Culver | P. Guénel | A. Dunning | D. Eccles | D. Evans | S. Bojesen | B. Nordestgaard | D. Kang | K. Yoo | R. Tollenaar | R. Milne | U. Hamann | A. Mannermaa | M. Shah | C. Clarke | A. Lindblom | M. Schmidt | M. Bolla | Qin Wang | T. Muranen | C. Blomqvist | H. Flyger | T. Truong | E. Sawyer | I. Tomlinson | S. Margolin | A. Jager | V. Arndt | R. Winqvist | M. Grip | A. Jakubowska | J. Lubiński | K. Matsuo | Hidemi Ito | A. Wu | S. Teo | M. Hartman | P. Pharoah | K. Egan | T. Park-Simon | D. Torres | M. Dwek | W. Tapper | M. Lush | D. Campa | F. Canzian | W. Newman | S. Gapstur | R. Kaaks | R. Keeman | Jyh‐cherng Yu | S. Hart | J. Lacey | M. U. Rashid | M. Troester | D. Plaseska-Karanfilska | W. Janni | A. Jung | M. Manoochehri | S. Brucker | Stella Koutros | J. García-Saenz | Sophia S. Wang | Sileny N. Han | N. Obi | H. Rennert | J. Heyworth | Christopher Scott | S. Mariapun | N. Håkansson | M. Gago-Domínguez | J. Castelao | Ji-Yeob Choi | C. Kitahara | H. Olsson | M. Gaudet | L. Schwentner | A. Romero | T. Ahearn | P. Auvinen | L. B. Beane Freeman | S. Behrens | A. Eliassen | M. Jakimovska | D. Mavroudis | N. Presneau | V. Rhenius | E. Saloustros | Xiaohong R. Yang | I. Briceño | P. Kapoor | A. Morra | M. Holmes | C. Petridis | A. Augustinsson | Reiner Hoppe | J. E. Castelao | Justin A. Williams | Thérèse Truong | M. Holmes | P. Hall | Mervi Grip | D. Evans | D. Hunter | Qin Wang | Thérèse Truong | A. Wu | D. Plaseska‐Karanfilska | Diana Torres | D. Evans
[1] C. Friedenreich,et al. Physical Activity and Mortality in Cancer Survivors: A Systematic Review and Meta-Analysis , 2019, JNCI cancer spectrum.
[2] J. Chang-Claude,et al. Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors , 2019, Breast Cancer Research.
[3] V. Beral,et al. Menopausal hormone therapy and 20-year breast cancer mortality , 2019, The Lancet.
[4] Paul Madley-Dowd,et al. The proportion of missing data should not be used to guide decisions on multiple imputation , 2019, Journal of clinical epidemiology.
[5] Ruth M Pfeiffer,et al. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population , 2018, Breast Cancer Research.
[6] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[7] P. Bernard,et al. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer , 2017, Cancer.
[8] Si-ying Zhou,et al. Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies , 2017, Breast Cancer.
[9] Suyun Li,et al. Smoking and survival of breast cancer patients: A meta-analysis of cohort studies. , 2017, Breast.
[10] W. Willett,et al. Cigarette Smoking Before and After Breast Cancer Diagnosis: Mortality From Breast Cancer and Smoking-Related Diseases. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Kauczor,et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study , 2016, BMC Cancer.
[12] J. Chang-Claude,et al. Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort , 2015, International journal of cancer.
[13] R. Wolff,et al. Pre-diagnostic breastfeeding, adiposity, and mortality among parous Hispanic and non-Hispanic white women with invasive breast cancer: the Breast Cancer Health Disparities Study , 2016, Breast Cancer Research and Treatment.
[14] Charles M. Perou,et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy , 2015, BMC Medicine.
[15] M. Bracken,et al. Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. , 2015, Journal of the National Cancer Institute.
[16] A. Olshan,et al. Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[17] I. Stijleman,et al. Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival. , 2015, Journal of the National Cancer Institute.
[18] A. McTiernan,et al. Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] L. Holmberg,et al. Recent childbirth is an adverse prognostic factor in breast cancer and melanoma, but not in Hodgkin lymphoma. , 2013, European journal of cancer.
[20] Lihong Qi,et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. , 2013, Journal of the National Cancer Institute.
[21] C. Shimizu,et al. Impact of recent parity on histopathological tumor features and breast cancer outcome in premenopausal Japanese women , 2013, Breast Cancer Research and Treatment.
[22] C. Smee,et al. United Kingdom , 2000, International Journal of Pharmaceutical Medicine.
[23] L. Vatten,et al. Association of time since last birth, age at first birth and parity with breast cancer survival among parous women: A register‐based study from Norway , 2013, International journal of cancer.
[24] Patrick Neven,et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. , 2011, Human molecular genetics.
[25] R. Gelber,et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] B. Strom,et al. Oral Contraceptive Use and Survival in Women with Invasive Breast Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[27] Victoria L. Cafourek,et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. , 2011, Journal of the National Cancer Institute.
[28] K. Kerlikowske,et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers , 2011, Cancer Causes & Control.
[29] J. Manson,et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.
[30] G. Giles,et al. Prediagnosis Reproductive Factors and All-Cause Mortality for Women with Breast Cancer in the Breast Cancer Family Registry , 2009, Cancer Epidemiology Biomarkers & Prevention.
[31] D. Easton,et al. Risk factors for the incidence of breast cancer: do they affect survival from the disease? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] P. Hall,et al. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study , 2008, Breast Cancer Research.
[33] Jason Hsia,et al. Oral Contraceptives and the Risk of Death From Breast Cancer , 2007, Obstetrics and gynecology.
[34] R. Coates,et al. Oral Contraceptives and Survival in Breast Cancer Patients Aged 20 to 54 Years , 2007, Cancer Epidemiology Biomarkers & Prevention.
[35] Michael J Pencina,et al. Choice of time scale and its effect on significance of predictors in longitudinal studies , 2007, Statistics in medicine.
[36] D. Petitti,et al. Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study , 2005, British Journal of Cancer.
[37] A. Hanlon,et al. Parity confers better prognosis in older women with early-stage breast cancer treated with breast-conserving therapy. , 2004, Clinical breast cancer.
[38] P. Wingo,et al. Reproductive History and Mortality After Breast Cancer Diagnosis , 2004, Obstetrics and gynecology.
[39] G. Giles,et al. Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] E. Franssen,et al. Are medical oncologists biased in their treatment of the large woman with breast cancer? , 2001, Breast Cancer Research and Treatment.
[41] L. Meurer,et al. Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis. , 2002, The Journal of family practice.
[42] Wendy Demark-Wahnefried,et al. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] G. Reeves,et al. Hormonal and other factors in relation to survival among breast cancer patients , 2000, International journal of cancer.
[44] A. Zauber,et al. Relation of time since last birth and parity to survival of young women with breast cancer. , 1998, Epidemiology.
[45] Julian Peto,et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.
[46] A. Lethaby,et al. Survival of women with node negative breast cancer in the Auckland region. , 1996, The New Zealand medical journal.
[47] P. Tartter,et al. Reproductive history and prognosis in patients with operable breast cancer , 1994, Cancer.